Evidence map›Paper›PMID 42321604›Full record

Observational studyBMC gastroenterology2026

Integrating serological markers of Helicobacter pylori and pepsinogen to improve detection of gastric precancerous conditions.

Zetian Chen, Hongxin Huang, Huimin Tao, Rui Wu, Zekuan Xu, Qiang Zhan, Zheng Li

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zetian Chen *Gastric Cancer Center, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, P. R. China.
Hongxin Huang *Gastric Cancer Center, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, P. R. China.
Huimin Tao *Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, P. R. China.
Rui WuDepartment of Gastroenterology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214023, P. R. China.
Zekuan XuGastric Cancer Center, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, P. R. China. xuzekuan@njmu.edu.cn.
Qiang ZhanDepartment of Gastroenterology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214023, P. R. China. 428559452@qq.com.
Zheng LiGastric Cancer Center, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, P. R. China. soslizheng@njmu.edu.cn.

Funding

Jiangsu Province Hospital (the First Affiliated Hospital with Nanjing Medical University) Clinical Capacity Enhancement Project JSPH-MC-2022-12National Natural Science Foundation of China 82072708Postgraduate Research & Practice Innovation Program of Jiangsu Province SJCX25_0071the Youth Program of National Natural Science Foundation of China 82002562
6 · The paper itself

Abstract

backgroundGastric cancer (GC) remains a significant global health burden due to its high incidence and mortality, especially in China. This study aimed to evaluate the performance of combined serological assessment of pepsinogen (PG) and Helicobacter pylori (H. pylori) antibodies for identifying gastric precancerous conditions.

methodsFrom November 2016 to September 2019, an observational cohort study was performed to evaluate serum levels of PG and H. pylori antibodies. Among 19,879 participants, four groups were defined based on serological status: Group A (PG

resultsGroup C demonstrated significantly elevated odds of atrophic gastritis (AG) (OR = 1.98; 95% CI: 1.17-3.26) and intestinal metaplasia (IM) (OR = 1.40; 95% CI: 0.73-2.67) compared to Group A. In the gastric corpus, the odds of AG and IM were 5.0 and 6.8 times higher, respectively, in Group C versus Group A.

conclusionCombined serological assessment of PG and anti- H. pylori IgG improves the identification of gastric precancerous conditions, with particularly enhanced performance in the gastric corpus.

Indexed as

Antibodies, BacterialHelicobacter InfectionsHelicobacter pyloriPepsinogen APrecancerous ConditionsStomach NeoplasmsAdultAgedBiomarkersCohort StudiesFemaleGastritis, AtrophicHumansMaleMetaplasiaMiddle AgedAntibodies, BacterialBiomarkersPepsinogen AABC classificationAtrophic gastritisGastric cancerHelicobacter pyloriPepsinogen assay

Identifiers

PMID42321604
PMCPMC13528030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.